Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies
Current Oncology · 03.03.2026 · 33 (3) · 148
DOI: 10.3390/curroncol33030148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 03.03.2026. Verfasst von Austin Frisch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI.
Abstract (Originalsprache)
KRAS-targeted therapy has opened new doors in the world of oncology, and many trials are underway for KRAS specific treatments for gastrointestinal (GI) malignancies. Outlining the current state of KRAS therapy and the remaining research gaps pertaining to these deadly cancers is crucial for the development of future therapeutics. In this review, we focus on the relationship between KRAS and GI malignancies. Current therapies are discussed with an in-depth exploration of the KRAS gene and how it connects to pancreatic, colorectal and other GI malignancies. Promising clinical trials and future therapies are highlighted while discussing the molecular biology behind them. Specifically, trials focusing on upcoming KRAS on and off inhibitors in development as well as variant focused inhibitors targeting the more common mutations G12D and G12V. We discuss exciting new pan/multi KRAS inhibitors that have been successful in pre-clinical trials. More unique therapeutic options include KRAS T cell therapies, vaccines, and combination strategies with immunotherapy. Furthermore, we address the difficulties with KRAS therapy, and the potential future directions needed to overcome them. An in-depth current literature review was done along with a review of the active clinical trials for KRAS-targeted therapeutics involving GI malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
- Inova Schar Cancer Center, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Harvard Medical School, Boston, MA 02115, USA.
- Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
- George Washington (GW) Cancer Center, Washington, DC 20037, USA.
ORCID-Profile: Srivatsan Raghavan
Förderung
- NCI NIH HHS
- NCI
Zitieren
APA
Frisch, A., Martin, E., Cannon, T., Wadlow, R., Raghavan, S., Sen, T., & Karim, N. A. (2026). Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies. Current Oncology, 33(3), 148. https://doi.org/10.3390/curroncol33030148
Vancouver
Frisch A, Martin E, Cannon T, Wadlow R, Raghavan S, Sen T, et al. Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies. Current Oncology. 2026;33(3):148. doi:10.3390/curroncol33030148
BibTeX
@article{Frisch2026,
author = {Frisch, Austin and Martin, Eric and Cannon, Timothy and Wadlow, Raymond and Raghavan, Srivatsan and Sen, Triparna and Karim, Nagla Abdel},
title = {Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {3},
pages = {148},
doi = {10.3390/curroncol33030148}
}
EUVIMED